Regardless, fisetin treatment abrogated RSK phosphorylation at threonine359/serine363 and decreased MDR1 levels in YB-1 overexpressing WM35 melanoma cells (Fig. 4G, Sup. The gene discussed is RPS6KA3; the disease is melanoma.